NUSHAMA AND AWAKN BRING REVOLUTIONARY ALCOHOL USE DISORDER TREATMENT TO NEW YORK — EFFICACY AT A FRACTION OF THE USUAL COST
Leading Psychedelic Therapy Protocol Available to Treat Alcoholism with NEW Partnership
NEW YORK, NY – Nov. 16, 2022 – Nushama exists to humanize medicine, providing sustained relief from depression, anxiety, chronic pain, addiction and trauma-induced mood disorders with high-dose IV ketamine for an ego-dissolving psychedelic experience. Awakn Life Sciences is a biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD). Together, they are bringing Awakn’s groundbreaking ketamine-assisted therapy treatment for AUD to New York for the first time at Nushama with plans to grow throughout the Northeast.
Alcohol Use Disorder (AUD) is a devastatingly serious condition that affects approximately 285 million people globally and results in more than 5% of all deaths. In the U.S., only 8% of those suffering from AUD seek treatment, and 75% of them relapse within the first 12 months. The pandemic has resulted in more people resorting to alcohol, and the rates of addiction are increasing at alarming rates.
Nushama, Awakn’s first licensed partner in the Northeast, will use the organization’s proprietary ketamine-assisted therapy protocol for the treatment of AUD. It is the only therapeutics package for ketamine and therapy validated in a clinical trial and has been proven to be more effective than any other addiction treatment currently available. Led by world-renowned ketamine expert Prof. Celia Morgan, results from the trial show 86% abstinence at six months post-treatment—in context, the average rate of abstinence before the treatment was 2%.
“People often abuse alcohol to cope with trauma—with this protocol’s combination of psychedelic medicine and therapy, participants discover the underlying reasons for their addiction, process their trauma, and can make lasting change,” said Nushama Co-Founder and President Richard Meloff. “Awakn has assembled one of the finest scientific teams in the world for the study of psychedelics and the treatment of addiction. Given the staggeringly high relapse rates, we felt an urgency to offer a new solution that is both efficacious and cost-effective. We’re thrilled to partner with Awakn to deliver this much-needed innovation to treat one of the most challenging addictions of all.”
Traditional AUD rehabilitation facilities range nationally from $20,000 to $65,000 per month and start at $50,000 in NYC. However, the Awakn protocol at Nushama costs a one-time fee of $12,500, a fraction of such facilities with superior efficacy rates. Awakn’s renowned team also includes Dr. Ben Sessa
, featured in Michael Pollan’s book-based series on NETFLIX, “How to Change Your Mind,” and Prof. David Nutt, Chief Research Officer.
“Awakn is proud to partner with Nushama and their exceptional team of clinicians in one of the world’s largest markets,” said Anthony Tennyson, Awakn’s, Chief Executive Officer. “Nushama has quickly established itself as a leader in this space and there is a shared understanding between us that the current standard of care for the treatment of alcohol addiction just isn’t good enough. We will work together to deliver a more efficacious and cost effective treatment to the growing number of people who so desperately need it in New York and the Northeast.”
ABOUT
Nushama is driven to heal a growing mental health crisis through the evidence-led power of psychedelics. Guided by a team with deep and recognized expertise in mental health, design, and community building, Nushama applies hospitality to medicine and provides a holistic path of mindful intention setting, ketamine journeys, and thoughtful integration in safe, healing-focused settings. Nushama provides sustained relief from depression, anxiety, chronic pain, addiction and trauma-induced mood disorders with high-dose intravenous (IV) ketamine for an ego-dissolving psychedelic experience and intramuscular (IM) ketamine protocols for groups. Medically led, Nushama is committed to learning from and integrating the latest psychedelic science with ancient teachings to help its members reset and reconnect.
Awakn Life Sciences Corp (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’) is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat substance and behavioral addictions. Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting 400m people globally for which the current standard of care is inadequate. Awakn’s goal is to provide effective therapeutics to addiction sufferers in desperate need and its strategy is focused on commercializing their R&D pipeline across multiple channels.
MEDIA CONTACT
Marissa Feinberg
marissa.feinberg@nushama.com
917-494-5041
